• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

New Onset of Inflammatory Bowel Disease in Three Patients Undergoing IL-17A Inhibitor Secukinumab: A Case Series.

作者信息

Vernero Marta, Astegiano Marco, Ribaldone Davide Giuseppe

机构信息

Department of General and Specialist Medicine, Gastroenterologia-U, Città della Salute e della Scienza di Torino, C.so Bramante 88, 10126, Turin, Italy.

Division of Gastroenterology, Department of Medical Sciences, Molinette Hospital, University of Turin, Turin, Italy.

出版信息

Am J Gastroenterol. 2019 Jan;114(1):179-180. doi: 10.1038/s41395-018-0422-z.

DOI:10.1038/s41395-018-0422-z
PMID:30429591
Abstract
摘要

相似文献

1
New Onset of Inflammatory Bowel Disease in Three Patients Undergoing IL-17A Inhibitor Secukinumab: A Case Series.3例接受白细胞介素-17A抑制剂司库奇尤单抗治疗的患者新发炎症性肠病：病例系列
Am J Gastroenterol. 2019 Jan;114(1):179-180. doi: 10.1038/s41395-018-0422-z.
2
Emergence of Inflammatory Bowel Disease During Treatment With Secukinumab.在使用司库奇尤单抗治疗期间出现炎症性肠病。
J Crohns Colitis. 2018 Aug 29;12(9):1131-1133. doi: 10.1093/ecco-jcc/jjy063.
3
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.司库奇尤单抗长期安全性经验：10 项中度至重度斑块型银屑病患者的 II 期和 III 期临床研究汇总分析。
J Am Acad Dermatol. 2016 Jul;75(1):83-98.e4. doi: 10.1016/j.jaad.2016.03.024. Epub 2016 May 12.
4
Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease.白细胞介素-17抑制：在银屑病和炎症性肠病中的作用。
J Dermatolog Treat. 2018 Feb;29(1):13-18. doi: 10.1080/09546634.2017.1329511. Epub 2017 May 31.
5
Inflammatory Bowel Disease Onset During Secukinumab Treatment: Real Concern or Just an Expression of Dysregulated Immune Response?在司库珠单抗治疗期间出现炎症性肠病：真的令人担忧，还是仅仅是免疫反应失调的表现？
Clin Drug Investig. 2019 Aug;39(8):799-803. doi: 10.1007/s40261-019-00803-7.
6
Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors.接受白细胞介素 17 抑制剂治疗的银屑病患者新发炎症性肠病的真实世界风险。
J Am Acad Dermatol. 2020 Aug;83(2):382-387. doi: 10.1016/j.jaad.2020.04.010. Epub 2020 Apr 11.
7
IL-17 inhibitors for psoriasis.用于治疗银屑病的白细胞介素-17抑制剂
Semin Cutan Med Surg. 2018 Sep;37(3):148-157. doi: 10.12788/j.sder.2018.051.
8
Secukinumab (AIN-457) for the treatment of Psoriasis.司库奇尤单抗（AIN-457）用于治疗银屑病。
Expert Rev Clin Pharmacol. 2016;9(2):187-202. doi: 10.1586/17512433.2016.1129894.
9
Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.白细胞介素-17（IL-17）抑制剂治疗斑块状银屑病的综述
Skin Therapy Lett. 2015 Jan-Feb;20(1):1-5.
10
Gastroenterological safety of IL-17 inhibitors: a systematic literature review.IL-17 抑制剂的胃肠安全性：系统文献回顾。
Expert Opin Drug Saf. 2022 Feb;21(2):223-239. doi: 10.1080/14740338.2021.1960981. Epub 2021 Aug 6.

引用本文的文献

1
Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis.接受五种不同白细胞介素抑制剂治疗的银屑病患者新发炎症性肠病的风险：一项系统评价和荟萃分析
Front Immunol. 2025 Jun 4;16:1594998. doi: 10.3389/fimmu.2025.1594998. eCollection 2025.
2
The role of fibroblast-neutrophil crosstalk in the pathogenesis of inflammatory diseases: a multi-tissue perspective.成纤维细胞-中性粒细胞相互作用在炎症性疾病发病机制中的作用：多组织视角
Front Immunol. 2025 May 23;16:1588667. doi: 10.3389/fimmu.2025.1588667. eCollection 2025.
3
IL-17A inhibitor-induced ulcerative colitis treated with an anti-IL-23 antibody.
用抗IL-23抗体治疗白细胞介素-17A抑制剂诱导的溃疡性结肠炎。
Clin J Gastroenterol. 2025 Jun 2. doi: 10.1007/s12328-025-02153-8.
4
Psoriasis and inflammatory bowel disease: concomitant IMID or paradoxical therapeutic effect? A scoping review on anti-IL-12/23 and anti-IL-23 antibodies.银屑病与炎症性肠病：是合并存在的免疫介导性炎症性疾病还是矛盾的治疗效果？关于抗IL-12/23和抗IL-23抗体的综述
Therap Adv Gastroenterol. 2024 Nov 21;17:17562848241299564. doi: 10.1177/17562848241299564. eCollection 2024.
5
Optimal Management of Refractory Crohn's Disease: Current Landscape and Future Direction.难治性克罗恩病的优化管理：现状与未来方向
Clin Exp Gastroenterol. 2024 Mar 26;17:75-86. doi: 10.2147/CEG.S359376. eCollection 2024.
6
Management of psoriatic arthritis: a consensus opinion by expert rheumatologists.银屑病关节炎的管理：风湿病专家的共识意见
Front Med (Lausanne). 2023 Nov 30;10:1327931. doi: 10.3389/fmed.2023.1327931. eCollection 2023.
7
The Intertwining Roads between Psychological Distress and Gut Microbiota in Inflammatory Bowel Disease.炎症性肠病中心理困扰与肠道微生物群之间的交织之路
Microorganisms. 2023 Sep 9;11(9):2268. doi: 10.3390/microorganisms11092268.
8
IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis.白细胞介素-17抑制剂相关的炎症性肠病：一项基于文献和数据库分析的研究
Front Pharmacol. 2023 Mar 23;14:1124628. doi: 10.3389/fphar.2023.1124628. eCollection 2023.
9
Colonic Dilatation Complicating Acute Severe Ulcerative Colitis Managed Successfully with Accelerated Infliximab Dosing.结肠扩张并发急性重症溃疡性结肠炎，通过加速英夫利昔单抗给药成功治疗
Case Rep Gastroenterol. 2023 Feb 7;17(1):82-88. doi: 10.1159/000529152. eCollection 2023 Jan-Dec.
10
polysaccharides and capsaicin modulate inflammatory cytokines and colonic microbiota in colitis rats induced by dextran sulfate sodium.多糖和辣椒素调节葡聚糖硫酸钠诱导的结肠炎大鼠的炎性细胞因子和结肠微生物群。
J Clin Biochem Nutr. 2022 Nov;71(3):229-237. doi: 10.3164/jcbn.21-174. Epub 2022 Aug 19.